AA
BCRX icon

Ancora Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ancora Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60
Closed -$500 – 1804
2023
Q1 		$500 Buy
+60
New +$578 ﹤0.01% 1726

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ancora Advisors's BCRX Position: Q2 2023 in Review

Ancora Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 60 shares — an estimated $500 sold.

Ancora Advisors first reported a position in BCRX in Q1 2023 and held it in 1 quarter. The position peaked at $500 in Q1 2023. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • Ancora Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ancora Advisors sold 60 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $500.
  • Ancora Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Ancora Advisors's BioCryst Pharmaceuticals position peaked at $500 in Q1 2023.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Ancora Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.